Updated Austrian treatment algorithm in HER2+ metastatic breast cancer

被引：0
|
作者：
Rupert Bartsch
Simon Peter Gampenrieder
Gabriel Rinnerthaler
Edgar Petru
Daniel Egle
Andreas Petzer
Marija Balic
Ursula Pluschnig
Thamer Sliwa
Christian Singer
机构：
[1] Medical University of Vienna,Department of Medicine I, Division of Oncology
[2] Paracelsus Medical University Salzburg,Third Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center
[3] Medical University of Graz,University Hospital for Gynecology and Obstetrics, Clinical Department of Gynecology
[4] Medical University of Innsbruck,Department of Gynecology, Breast Cancer Center Tirol
[5] Ordensklinikum Linz GmbH,Barmherzige Schwestern, Elisabethinen, Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology
[6] Medical University of Graz,Department of Internal Medicine, Division of Clinical Oncology
[7] Klagenfurt Hospital,Department of Internal Medicine and Hematology and Internal Oncology
[8] Hanusch Hospital,3rd Medical Department, Hematology and Oncology
[9] Medical University of Vienna,Department of Gynecology, Breast Cancer Center Vienna
来源：
Wiener klinische Wochenschrift | 2022年 / 134卷
关键词：
HER2; Trastuzumab; Pertuzumab; Antibody-conjugate; Tyrosin-kinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.
引用
收藏
页码：63 / 72
页数：9
相关论文
共 50 条
  • [21] Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
    Rinnerthaler, Gabriel
    Singer, Christian
    Petru, Edgar
    Egle, Daniel
    Petzer, Andreas
    Pluschnig, Ursula
    Gampenrieder, Simon Peter
    Pfeiler, Georg
    Gnant, Michael
    Gruenberger, Birgit
    Krippl, Peter
    Strasser-Weippl, Kathrin
    Suppan, Christoph
    Brunner, Christine
    Pusch, Renate
    Sandholzer, Margit
    Balic, Marija
    Bartsch, Rupert
    WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (19-20) : 683 - 692
  • [22] Treatment landscape of patients with HER2+ early breast cancer: an overview
    Ting, Frederic Ivan L.
    ECANCERMEDICALSCIENCE, 2024, 18
  • [23] Adjuvant therapy of HER2+ breast cancer
    EP Winer
    Breast Cancer Research, 11
  • [24] HER2+ breast cancer: How to evaluate?
    Schmitt F.
    Advances in Therapy, 2009, 26 (Suppl 1) : S1 - S8
  • [25] Adjuvant therapy of HER2+ breast cancer
    Winer, E. P.
    BREAST CANCER RESEARCH, 2009, 11 : S6 - S6
  • [26] Symptom Burden and Quality of Life among Women with HER2+ Metastatic Breast Cancer
    Mayer, Musa
    Lang, Kathleen
    Hurvitz, Sara
    Lalla, Deepa
    Federico, Victoria
    Brammer, Melissa
    Menzin, Joseph
    Tripathy, Debu
    BREAST JOURNAL, 2015, 21 (02): : 208 - 210
  • [27] Survival, treatment patterns, and costs of HER2+ metastatic breast cancer patients in Ontario between 2005 to 2020
    S. J. Seung
    H. Saherawala
    D. Moldaver
    S. Shokar
    C. Ammendolea
    C. Brezden-Masley
    Breast Cancer Research and Treatment, 2024, 204 : 341 - 357
  • [28] Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR + metastatic breast cancer
    Loft, Matthew
    Lok, Sheau Wen
    De Boer, Richard
    Malik, Laeeq
    Greenberg, Sally
    Yeo, Belinda
    Anton, Angelyn
    Nottage, Michelle
    Wong, Vanessa
    Nott, Louise
    Collins, Ian M. M.
    Torres, Javier
    Barnett, Frances
    Lombard, Janine M. M.
    Gibbs, Peter
    Gately, Lucy
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 198 (01) : 67 - 74
  • [29] The benefits of trastuzumab in the treatment of HER2+ breast cancer as a function of exposure time
    Cordero da Luz, Felipe Andres
    Marinho, Eduarda da Costa
    Nascimento, Camila Piqui
    Marques, Lara de Andrade
    Ribeiro Delfino, Patricia Ferreira
    Antonioli, Rafael Mathias
    Barbosa Silva, Marcelo Jose
    de Araujo, Rogerio Agenor
    ECANCERMEDICALSCIENCE, 2022, 16
  • [30] A pathway to therapy for HER2+ metastatic biliary tract cancer
    Ray K.
    Nature Reviews Gastroenterology & Hepatology, 2021, 18 (10) : 676 - 676
12345